Thus, it can be seen that PTPRC, CD86, CCR5, and ITGAM could be considered as potential targets of PREDNISONE, EPOETIN BETA, ABATACEPT, MARAVIROC, and CLARITHROMYCIN, which may provide novel treatment options for kidney transplant patients with allograft rejection. Here, PTPRC is linked to medical procedure.